Adverum Climbs Out Of Abyss With Promising Early Gene Therapy Data In Wet AMD
The Phase II LUNA study of ixo-vec showed a reduction in anti-VEGF use and stabilization of visual acuity and anatomic parameters that Adverum – and some analysts – called best in class.
You may also be interested in...
The eye disease gene therapy 4D-150 posted highly impressive Phase II data, prompting a near-doubling of the company’s market value.
The company presented promising Phase II data, but it didn’t reveal its plans for a pivotal trial of ABBV-RGX-314, which would compete in a growing – but increasingly crowded – market.
The California-based biotech is reducing its workforce to help finance a Phase II study of Ixo-vec, its eye gene therapy which has been blighted by safety concerns.